Using glucocorticoids to treat intestinal injury from radiation

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to evaluate the efficacy and safety of glucocorticoids in treating acute radiation-induced intestinal injury in patients who have undergone radiotherapy. A total of 60 patients will be randomly assigned to receive either glucocorticoid treatment or standard care. The primary focus is on the recovery and improvement of intestinal injury, while secondary endpoints include monitoring for recurrence and adverse events. The study seeks to clarify the controversial role of glucocorticoids in managing this complication.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Grade II-III acute radiation-induced rectosigmoid injury
2. Signed informed consents
3. Age ≥18 years
4. Rstimated survival time \>1 year

Exclusion Criteria:

1. Absolute contraindications to glucocorticoids
2. A history of glucocorticoids treatment within 3 months
3. Inflammatory bowel disease or infectious intestinal disease
4. Recurrence of malignant tumor
5. Colorectal cancer or metastasis
6. Severe heart or lung diseases
7. Recent history of surgery or trauma
8. Poorly controlled hyperglycemia and hypertension
9. Active tuberculosis
10. Ssevere gastrointestinal ulcers
11. Glaucoma
12. Sychiatric diseases
13. Pregnant or lactating

Where it's running

• Department of Gastroenterology, General Hospital of Northern Theater Command (formerly called General Hospital of Shenyang Military Area)
  Shenyang, Liaoning, China Recruiting

Study contacts

• Principal investigator: Xingshun Qi — The General Hospital of Northern Theater Command
• Study coordinator: Xingshun Qi
• Email: xingshunqi@126.com
• Phone: 18909881019

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Pirfenidone for radiation-related and immune-related lung injury

  This trial will try pirfenidone capsules to treat adults who develop radiation-induced lung injury or immune checkpoint inhibitor–related pneumonitis.

  Recruiting at 36 sites Phase 2/3 Beijing Continent Pharmaceutical Co, Ltd. · Hefei, Anhui and 35 other locations · NCT07388680

• 4DCT-guided functional lung avoidance radiotherapy to spare high-function lung

  This study will test whether using 4DCT-derived lung ventilation maps to guide radiotherapy can better spare high-function lung in adults receiving thoracic IMRT or SBRT for lung cancer.

  Recruiting The Second Affiliated Hospital of Chongqing Medical University · Chongqing · NCT07339644

• Using incentive spirometry to help lung cancer patients during treatment

  This study is testing whether using an incentive spirometer can help lung cancer patients breathe better and feel healthier during and after their treatment.

  Recruiting Cooper Norcross Health · Camden, New Jersey · NCT06688422

• Using a new imaging probe to detect tissue damage from radiation in lung and pancreatic cancer patients

  This study is testing a new imaging probe to see if it can help find tissue damage from radiation in lung and pancreatic cancer patients.

  Recruiting Phase 2 Massachusetts General Hospital · Boston, Massachusetts · NCT04485286

• Akkermansia muciniphila topical probiotic to prevent and treat radiation skin injury

  A topical probiotic made from inactivated Akkermansia muciniphila is being tested to see if it is safe and tolerable for people getting radiotherapy for breast or head/neck cancers, to prevent or lessen radiation-induced skin damage.

  Recruiting at 2 sites Phase 1 West China Hospital · Chengdu, Sichuan and 1 other locations · NCT07635277

• Pneumonitis Prevention with Pentoxifylline and Vitamin E in Stage III NSCLC with Chemoradiation

  This trial tests whether adding pentoxifylline and vitamin E can help prevent radiation-induced lung injury in adults with stage III non-small cell lung cancer who are receiving chemoradiation and planned immune therapy.

  Recruiting Phase 2 University Health Network, Toronto · Toronto, Ontario · NCT06634056

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.